AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 DEC 5 - (NewsRx.com & NewsRx.net) -- BioSante Pharmaceuticals, Inc. (BTPH) has licensed its Bio-Vant vaccine adjuvant on a nonexclusive basis to Corixa Corp. (CRXA) for use in several potential vaccines to be developed by Corixa.
This agreement is a result of Corixa's completion of feasibility studies using Bio-Vant with certain Corixa protein antigens and DNA.
Said Stephen M. Simes, BioSante's president and chief executive officer, "Several other unannounced partner-funded feasibility studies also are underway with both biotech and pharmaceutical companies."
Under the agreement, Corixa has agreed to pay BioSante milestone payments upon the achievement by Corixa of certain milestones plus royalty payments on sales by Corixa if and when vaccines are approved using Bio-Vant and sold on a commercial basis. If Corixa sub-licenses vaccines that include Bio-Vant, BioSante will share in milestone payments and royalties received by Corixa. The license agreement covers access to Bio-Vant for a variety of cancer, infectious and autoimmune disease vaccines.
BioSante has developed its proprietary calcium phosphate nanoparticles, known as CAP, into a ...
Source: HighBeam Research, BioSante Licenses Vaccine Technology To Corixa Corp.(Brief Article)